RX pharmaceuticals

The priority goal of the company is the development and introduction to the world market of drugs based on peptide bioregulators. The company is creating 25 drugs. Currently, drugs are at different stages of pharmaceutical development and preclinical studies. 5 drugs completed the first phase of clinical trials, 1 is in the second phase.
  • BRAINIPEPT®
    Peptide drug for adrenal glands
  • ELVIPEPT®
    Peptide drug for gastric mucosa
  • CORAPEPT®
    Peptide drug for heart
  • PANCRAPEPT®
    Peptide drug for pancreas
  • EPINORM®
    Peptide drug for epithesis
  • NEFROPEPT®
    Peptide drug for kidneys
  • THYREOPEPT®
    Peptide drug for thyroid gland
  • T-34
    -
  • LANGOPEPT®
    Peptide drug for bronchi
  • Партнерство
    Перейти в раздел
  • О компании
    Перейти в раздел
  • Исследования
    Перейти в раздел